Suppr超能文献

定义用于治疗应用的间充质基质细胞(MSC)衍生的小细胞外囊泡。

Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications.

作者信息

Witwer Kenneth W, Van Balkom Bas W M, Bruno Stefania, Choo Andre, Dominici Massimo, Gimona Mario, Hill Andrew F, De Kleijn Dominique, Koh Mickey, Lai Ruenn Chai, Mitsialis S Alex, Ortiz Luis A, Rohde Eva, Asada Takashi, Toh Wei Seong, Weiss Daniel J, Zheng Lei, Giebel Bernd, Lim Sai Kiang

机构信息

Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

J Extracell Vesicles. 2019 Apr 29;8(1):1609206. doi: 10.1080/20013078.2019.1609206. eCollection 2019.

Abstract

Small extracellular vesicles (sEVs) from mesenchymal stromal/stem cells (MSCs) are transiting rapidly towards clinical applications. However, discrepancies and controversies about the biology, functions, and potency of MSC-sEVs have arisen due to several factors: the diversity of MSCs and their preparation; various methods of sEV production and separation; a lack of standardized quality assurance assays; and limited reproducibility of and functional assays. To address these issues, members of four societies (SOCRATES, ISEV, ISCT and ISBT) propose specific harmonization criteria for MSC-sEVs to facilitate data sharing and comparison, which should help to advance the field towards clinical applications. Specifically, MSC-sEVs should be defined by quantifiable metrics to identify the cellular origin of the sEVs in a preparation, presence of lipid-membrane vesicles, and the degree of physical and biochemical integrity of the vesicles. For practical purposes, new MSC-sEV preparations might also be measured against a well-characterized MSC-sEV biological reference. The ultimate goal of developing these metrics is to map aspects of MSC-sEV biology and therapeutic potency onto quantifiable features of each preparation.

摘要

间充质基质/干细胞(MSC)来源的小细胞外囊泡(sEV)正迅速走向临床应用。然而,由于多种因素,关于MSC-sEV的生物学特性、功能和效力出现了差异和争议:MSC的多样性及其制备方法;sEV产生和分离的各种方法;缺乏标准化的质量保证检测方法;以及功能检测的可重复性有限。为了解决这些问题,四个学会(SOCRATES、ISEV、ISCT和ISBT)的成员提出了针对MSC-sEV的具体协调标准,以促进数据共享和比较,这应有助于推动该领域向临床应用发展。具体而言,MSC-sEV应通过可量化指标来定义,以确定制剂中sEV的细胞来源、脂质膜囊泡的存在以及囊泡的物理和生化完整性程度。出于实际目的,新的MSC-sEV制剂也可与特征明确的MSC-sEV生物学参考物进行比较。制定这些指标的最终目标是将MSC-sEV生物学和治疗效力的各个方面映射到每种制剂的可量化特征上。

相似文献

引用本文的文献

5
Extracellular vesicles as biomarkers and drug delivery systems for tumor.细胞外囊泡作为肿瘤的生物标志物和药物递送系统
Acta Pharm Sin B. 2025 Jul;15(7):3460-3486. doi: 10.1016/j.apsb.2025.04.033. Epub 2025 May 10.

本文引用的文献

3
Human platelet lysate current standards and future developments.人血小板裂解液的现行标准和未来发展。
Transfusion. 2019 Apr;59(4):1407-1413. doi: 10.1111/trf.15174. Epub 2019 Feb 11.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验